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Most new drug treatments fail because they lack efficacy1. In sepsis research, new therapies must contend with an additional
barrier: the intractable heterogeneity of the sepsis syndrome2. Together, these challenges have so far proved insurmountable.
Hundreds of clinical trials have been conducted, at a cost of hundreds of millions of dollars, to test new agents to modulate the
host response to injury in sepsis. None has succeeded2.
The sepsis syndrome itself is simultaneously too broad and too narrow. Sepsis encompasses numerous different aetiologies and
pathophysiological processes, but - by definition3 - excludes sterile injuries that lead to the same pathophysiology and organ
failures, such as trauma, burns, haemorrhage and pancreatitis.
Some components of heterogeneity in sepsis are clinically apparent - for example, variability in causal pathogens, co-morbidities,
and environmental factors and host genetics. But there is also evidence from recent studies4,5,6 - that important pathophysiological
processes that are active in sepsis patients may vary in ways that are not directly observable at the bedside. If so, there is a
chance that these processes may be amenable to different treatments.
Large observational studies of blood transcriptomics applied to sepsis populations have provided several models based on molecular
classification of patients with sepsis. In particular, the Genomic Advances in Sepsis (GAinS) consortium in the United Kingdom4,6
and the Molecular diAgnosis and Risk stratification of Sepsis (MARS) consortium in the Netherlands detected distinct molecular
endotypes in leukocyte genome-wide expression profiles from samples collected on ICU admission. The MARS consortium
identified four molecular endotypes in all-cause sepsis (designated MARS 1-4)6, whereas the GAinS consortium identified two
molecular endotypes in community acquired pneumonia, designated as sepsis response signature (SRS) 1 and 24. More recently,
in an impressive demonstration of the power of open science and data sharing7, Sweeney et al identified three clinical signatures -
termed inflammopathic, coagulopathic and adaptive - using pooled data from publicly-available gene expression data from other
studies of patients with sepsis5. Both the MARS and SRS molecular endotypes were associated with different mortality rates.
This is a necessary first step. But after these observations, the question remains whether the MARS/SRS signatures relate to
therapeutically-targetable immunopathologies. Subgroups may reflect differing disease severity, or other features of the patients
that are irrelevant to their care. Evidence of a therapeutically-relevant difference between transcriptomic subgroups among
children with sepsis was provided by Hector Wong et al in 20148, but in that study, steroids were administered at physician’s
discretion. In order to demonstrate a treatment effect between two subgroups, it is necessary to acquire gene expression data
from patients enrolled in randomised clinical trials.
For the first time, direct evidence of such an effect is reported in this issue of AJRCCM by David Antcliffe et al. Using data
from the Vasopressin vs Norepinephrine as Initial Therapy in Septic Shock (VANISH) trial9, a generalized linear model based
on a previously identified seven gene SRS classifier (DYRK2, CCNB1IP1, TDRD9, ZAP70, ARL14EP, MDC1 and ADGRE3)
enabled the authors to stratify 176 patients as SRS1 (47%) or SRS2 (53%). Patients stratified in this fashion did not differ in
demographics and most baseline clinical characteristics (except for rates of ischaemic heart disease). However, in line with the
groups’ previous findings4, 28-day mortality in the placebo group was higher in SRS1 (37%) than in SRS2(8%)9. Serum lactate at
baseline was also higher in SRS1. Together these observations indicate that, to some extent, SRS classification reflects disease
severity.
If severity (rather than distinct pathophysiology) underlies the difference between these groups of patients, then an interaction
with steroid treatment might be anticipated. There are replicated trends in large trials of steroids in sepsis and septic shock10,11,
1
towards a possible treatment benefit in patients with the highest risk of death. Whether this trend is real, and if so, whether
it is simply a consequence of higher event rate in this group (heterogeneity of treatment effect), are open questions at present.
Based on these studies, we would have predicted a higher probability of detectable benefit from steroids among patients classified
as SRS1. In fact, an interaction was detected between hydrocortisone use and SRS2-classified patients resulting in increased
mortality estimates with adjusted odds ratio of 8.3 (95% confidence interval 1.4-47.8). That is, a signal consistent with harm
from steroid treatment in the less-severe SRS2-classified group.
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Figure 1: Diagnosis and treatment of treatable traits in a patient population.
Collectively, these results, together with therapeutic trials using sub-classifications of acute respiratory distress syndrome
(ARDS)12,13, imply that there are divergent effects from a single intervention across and in different patient endotypes, bringing
them closer to the definition of a true disease endotype14.
The investigators in the VANISH trial are to be congratulated for having the foresight to acquire transcriptomic data within a
randomised controlled trial. Although confirmatory replication will be necessary, this work brings us a step closer to the primary
aim of stratified medicine research: new phenotypes with direct therapeutic consequences. It is our view that future clinical
trials in critical illness should consider from the outset the probability that any new therapy may have a differential effect in a
subgroup of patients, and that subgroup may only be identifiable through deep phenotyping. Of the available methodologies,
whole blood RNA in preservative is the most pragmatic sample to acquire to enable future enable deep phenotyping.
The dichotomy SRS1/2 classification simplifies analysis, but the groupings are drawn by bisecting what appears to be a unimodal
distribution4. This suggests that the SRS classification reflects two extremes a continuously varying underlying biological process.
This move from the identification of subgroups to the detection of continous “treatable traits” within clinical populations has
become a major focus of work in other fields14; we, and many others, would argue that sepsis research is in particular need of
these new approaches2. Going further, it is very plausible that any physiological process that is active in a large proportion of
patients with sepsis, will also be active in some patients with severe sterile injury. As with other therapeutic approaches in critical
care medicine, new treatable traits may be generalisable across critical illness.
If the information necessary to predict response to a given therapy is present in measured clinical variables, or in the whole blood
transcriptome, then detecting it becomes entirely a matter of data analysis. With current techniques, huge numbers of patients
will be needed to overcome signal:noise ratios. Integration of transcriptomic signatures with genetic associations15, may enable
more efficient detection of key underlying processes. Ultimately these approaches may identify new, specific drug targets to
modulate the host response to critical injury16, and actionable estimates of individual treatment effect for critically ill patients.
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